Devonian Health Group advances Thykamine with human liver-on-a-chip data targeting fibrosis in MASH
Devonian Health Group reports human liver-on-a-chip data for Thykamine in MASH. See what this means for fibrosis-focused drug development.
From ingredients to devices: what BON Natural Life Limited’s apple mask means for medical aesthetics innovation
Explore how BON Natural Life Limited’s bio-electronic apple polyphenol mask could reshape medical aesthetics if clinical data holds up.
Menopause-specific hair loss enters the clinical spotlight after KilgourMD trial data
KilgourMD’s phase II data challenges how menopause-related hair loss is studied and treated. See what changes and what clinicians will watch next.
Ambient-temperature RNA-ISH enters mainstream pathology as Molecular Instruments expands HCR Pro automation
Discover how Molecular Instruments’ ambient-temperature HCR Pro RNA-ISH on BOND-III could reshape clinical pathology automation and RNA diagnostics.
How Seek Labs’ CRISPR platform could change the economics of avian influenza outbreaks
Seek Labs secures USDA funding for a CRISPR-based avian flu therapeutic. Find out why mutation-resistant platforms may redefine HPAI response.
Life Spine strengthens ProLift’s long-term viability as MRI compatibility becomes a procurement baseline
Life Spine confirms MR Conditional status for ProLift. Find out why MRI compatibility now defines spine implant viability rather than differentiation.
Why Project Santa Fe Foundation and Virchow Medical are testing a proactive future for oncology diagnostics
Project Santa Fe Foundation and Virchow Medical are redefining oncology diagnostics through proactive analytics. Find out what this changes for labs and clinicians.
STAAR Surgical advances EVO ICL adoption as FDA approval reframes high-myopia treatment economics
FDA expands EVO ICL use to ages 21–60. Discover what this means for refractive surgery, safety data, and the shift away from laser vision correction.
What Avidity Biosciences Phase 1/2 MARINA results reveal about the future of DM1 drug development
NEJM publication of Avidity Biosciences delpacibart etedesiran data raises new questions for DM1 treatment. Discover what this changes next.
Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.